Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Silent Aspiration Following Extubation in the ICU (SAFE-ICU)

3 de junio de 2026 actualizado por: Jihad Mallat, Cleveland Clinic Abu Dhabi

Incidence, Risk Factors, and Outcomes of Silent Aspiration Post Extubation in the ICU

Post-extubation dysphagia is common in critically ill patients and may lead to silent aspiration, which often remains undetected because patients do not exhibit overt clinical signs such as coughing or choking. Current bedside nursing swallow screening may fail to identify silent aspiration in patients recovering from prolonged mechanical ventilation.

The goal of this observational study is to learn about the incidence, risk factors, and clinical outcomes of silent aspiration in critically ill adult patients who require prolonged mechanical ventilation and are extubated in the ICU. The main questions it aims to answer are:

  • How often does silent aspiration occur in ICU patients intubated for 5 days or longer after extubation?
  • Can silent aspiration be present despite passing the routine bedside nursing swallow screen?
  • What clinical factors are associated with silent aspiration?
  • Is silent aspiration associated with worse clinical outcomes such as aspiration pneumonia, reintubation, prolonged ICU stay, ventilator-free days, or mortality? Participants who have been mechanically ventilated for 5 days or more will undergo routine bedside swallow screening followed by Fiberoptic Endoscopic Evaluation of Swallowing (FEES), considered the gold-standard diagnostic tool for detecting silent aspiration, within 72 hours after extubation. Researchers will compare bedside nursing swallow screening results with FEES findings to evaluate the diagnostic accuracy of bedside screening in detecting silent aspiration. Clinical data, swallowing assessment findings, and patient outcomes will also be collected and analyzed.

Descripción general del estudio

Descripción detallada

Background:

Post-extubation dysphagia (PED) is common in critically ill patients and is often multifactorial in origin, resulting from trauma, neuromuscular weakness, altered sensation, impaired cognition, and desynchronized breathing-swallowing coordination. Silent aspiration - defined as entry of oropharyngeal material below the vocal folds without overt clinical signs such as coughing or choking - has been reported in up to 69.3% of ICU patients undergoing instrumental assessment. Despite this, current clinical practice at many centers does not mandate instrumental swallow evaluation for patients who pass routine bedside nursing swallow screening.

Study Design:

This is a prospective observational study conducted in the ICU at Cleveland Clinic Abu Dhabi (CCAD). Informed consent will be obtained from all patients or their next of kin prior to enrollment.

Participants:

Adult ICU patients who have been mechanically ventilated for 5 or more days and are subsequently extubated will be eligible for enrollment. Exclusion criteria include: (1) tracheostomy; (2) do-not-reintubate orders; (3) pregnancy; and (4) absence of informed consent.

Procedures:

All enrolled patients will undergo the standard bedside nursing swallow screen per institutional protocol (CCAD PolicyTech). For the purpose of this study, Fiberoptic Endoscopic Evaluation of Swallowing (FEES) will be performed in all enrolled patients up to 72 hours of extubation, regardless of bedside screening results. FEES is a well-established, safe, and portable instrumental assessment that allows direct visualization of pharyngeal and laryngeal structures and detection of aspiration, including silent aspiration. FEES will only be performed after approval by the treating attending physician, and patients with contraindications (e.g., high bleeding risk, high oxygen requirements) will be excluded from the procedure.

Assessments:

FEES findings will be reported using standardized validated scales including the Penetration-Aspiration Scale (PAS), Dysphagia Severity Rating Scale (DSRS), Pharyngeal Residue Severity Rating Scale (PRSS), Murray Secretion Scale, and Airway Protection Scale. Clinical data collected will include age, sex, admitting diagnosis, reasons for intubation, duration of mechanical ventilation, oxygen requirements, bedside swallow screen findings, and clinical outcomes including aspiration pneumonia, reintubation, ventilator-free days, ICU and hospital length of stay, and mortality.

Statistical Analysis:

Descriptive statistics will be used to report the incidence of silent aspiration. Diagnostic accuracy (sensitivity, specificity, Cohen's kappa) of bedside nursing screening will be calculated using FEES as the reference standard. Multivariable logistic regression will identify independent predictors of silent aspiration and its association with clinical outcomes. A minimum sample of 274 patients will be recruited (based on an expected 20% incidence, 95% CI, 5% margin of error, 10% loss to follow-up).

Tipo de estudio

De observación

Inscripción (Estimado)

274

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jihad Mallat, MD, PhD
  • Número de teléfono: +97125019000
  • Correo electrónico: mallatj@ccad.ae

Ubicaciones de estudio

      • Abu Dhabi, Emiratos Árabes Unidos
        • Cleveland Clinic Abu Dhabi
        • Contacto:
          • Jihad Mallat, MD PhD
          • Número de teléfono: +97125019000
          • Correo electrónico: mallatj@ccad.ae

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Adult critically ill patients admitted to the ICU who require prolonged invasive mechanical ventilation (5 days or longer) and undergo extubation. Participants will undergo bedside swallow screening and FEES evaluation after extubation to assess for silent aspiration and post-extubation dysphagia.

Descripción

Inclusion Criteria:

  • Adult ICU patients requiring invasive mechanical ventilation for 5 days or longer
  • Successful extubation after invasive mechanical ventilation
  • Undergoing bedside nursing swallow screening after extubation
  • Ability to undergo Fiberoptic Endoscopic Evaluation of Swallowing (FEES) within 72 hours after extubation
  • Provision of informed consent by the patient or legally authorized representative

Exclusion Criteria:

  • Presence of tracheostomy
  • Do-not-reintubate orders/Allow natural death
  • Pregnancy
  • Absence of informed consent
  • Contraindication to FEES as determined by the treating physician (e.g., high bleeding risk or severe oxygen requirements)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
ICU Patients Following Prolonged Mechanical Ventilation
Adult ICU patients intubated for 5 days or longer undergoing bedside swallow screening and Fiberoptic Endoscopic Evaluation of Swallowing (FEES) within 72 hours after extubation to assess silent aspiration
FEES will be performed within 72 hours after extubation to assess swallowing function and detect silent aspiration in ICU patients following prolonged mechanical ventilation.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Silent Aspiration After Extubation
Periodo de tiempo: Up to 72 hours after extubation
Silent aspiration identified by Fiberoptic Endoscopic Evaluation of Swallowing (FEES) in ICU patients intubated for 5 days or longer after extubation
Up to 72 hours after extubation

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic Accuracy of Bedside Swallow Screening
Periodo de tiempo: Up to 72 hours after extubation
Sensitivity and specificity of bedside nursing swallow screening for detecting silent aspiration using FEES as the reference standard
Up to 72 hours after extubation
Aspiration Pneumonia
Periodo de tiempo: Up to 30 days after extubation
Incidence of aspiration pneumonia following extubation
Up to 30 days after extubation
Reintubation
Periodo de tiempo: Up to 30 days after extubation
Need for reintubation after extubation
Up to 30 days after extubation
Ventilator-Free Days
Periodo de tiempo: 28 days
Number of ventilator-free days after extubation
28 days
ICU Length of Stay
Periodo de tiempo: Up to 24 weeks
Length of ICU stay after extubation
Up to 24 weeks
Hospital length of stay
Periodo de tiempo: Up to 26 weeks
Total hospital length of stay
Up to 26 weeks
ICU Mortality
Periodo de tiempo: Up to 24 weeks
Death occurring during ICU stay
Up to 24 weeks
Hospital Mortality
Periodo de tiempo: Up to 26 weeks
Death occurring during hospitalization
Up to 26 weeks
Risk Factors Associated With Silent Aspiration
Periodo de tiempo: Up to 26 weeks
Clinical factors independently associated with silent aspiration identified using multivariable analysis
Up to 26 weeks
Duration of Dysphagia
Periodo de tiempo: Up to 3 months
Duration of post-extubation dysphagia identified by FEES
Up to 3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Jihad Mallat, MD, PhD, Cleveland Clinic Abu Dhabi

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de junio de 2026

Finalización primaria (Estimado)

1 de junio de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

17 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de junio de 2026

Publicado por primera vez (Actual)

9 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de junio de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir